Refractory myasthenia gravis treated with autologous hematopoietic stem cell transplantation
Annals of Clinical and Translational Neurology · 2025
DOI: 10.1002/acn3.52246 ↗At a glance
Journal article in Annals of Clinical and Translational Neurology, 2025. Written by Benjamin Beland and 12 co-authors. Institution: Division of Neurology, Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Major MEDLINE topics: Myasthenia Gravis, Hematopoietic Stem Cell Transplantation. Cited 9 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Objectives
Patients with refractory myasthenia gravis (MG) have few treatment options. Autologous hematopoietic stem cell transplantation (HSCT) has been used to treat immune diseases; however, its use in the treatment of MG is not broadly considered. Our objective is to report on the efficacy and safety of HSCT in refractory MG.
Methods
Twenty‐one patients who underwent HSCT for MG were retrospectively reviewed. All patients had severe MG refractory to multiple therapies. Stem cells were mobilized with cyclophosphamide and granulocyte colony‐stimulating factor. The grafts were depleted of immune cells by selecting CD34+ cells. HSCT conditioning consisted of high‐dose cytoreductive therapy and anti‐thymocyte globulin. The primary efficacy outcome was achieving clinically stable remission or minimal manifestations without treatment and remaining as such until most recent follow‐up.
Results
The median time from MG diagnosis to HSCT was 4.0 years. The primary outcome was reached in 16 of 18 evaluable patients (89%) at a median of 1.7 years and maintained with a median follow‐up of 6.7 years (range 1.0–21.9 years). Three patients were not evaluable for the primary outcome: one due to confounding illness and two died within 12 months of transplant. The transplant‐related mortality at 100 days was 9.5%. Two late deaths occurred, with uncertain relation to the HSCT.
Interpretation
After HSCT for refractory MG, most patients achieved sustained disease remission. However, HSCT‐related mortality in medically complex MG patients may be high. Prospective studies investigating the efficacy and safety of HSCT in the treatment of refractory MG are warranted.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Division of Neurology, Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Division of Hematology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Transplant and Cell Therapy Program, Division of Hematology, Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
- Division of Neurology, Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
ORCID profiles: Benjamin Beland
Cite
APA
Beland, B., Storek, J., Quartermain, L., Hahn, C., Pringle, C. E., Bourque, P. R., Kennah, M., Kekre, N., Bredeson, C., Allan, D., Jamani, K., White, C., & Atkins, H. (2025). Refractory myasthenia gravis treated with autologous hematopoietic stem cell transplantation. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52246
Vancouver
Beland B, Storek J, Quartermain L, Hahn C, Pringle CE, Bourque PR, et al. Refractory myasthenia gravis treated with autologous hematopoietic stem cell transplantation. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.52246
BibTeX
@article{Beland2025,
author = {Beland, Benjamin and Storek, Jan and Quartermain, Liam and Hahn, Christopher and Pringle, C Elizabeth and Bourque, Pierre R and Kennah, Michael and Kekre, Natasha and Bredeson, Christopher and Allan, David and Jamani, Kareem and White, Christopher and Atkins, Harold},
title = {Refractory myasthenia gravis treated with autologous hematopoietic stem cell transplantation},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
doi = {10.1002/acn3.52246}
}
EUVIMED